Sensex Ends Flat, Nifty Gains 0.23 Pc As Investors Assess Fed Policy Outcome
(MENAFN - IANS) Mumbai, Sep 17 (IANS) Indian benchmark indices ended the session on a muted note on Thursday as investors assessed the outcome of the US Federal Reserve's policy meeting and its ...
2026-09-17 06:46:17

Bengaluru: Family Dispute Suspected Behind Deadly Attack On Bengal Nurse By Estranged Husband From TN (Ld)
(MENAFN - IANS) Bengaluru, Sep 17 (IANS) A family dispute is suspected to have been the reason behind the deadly attack in Bengaluru on a 26-year-old nurse from West Bengal, allegedly by her ...
2026-09-17 06:46:15

India Seeks Technology-Driven Competitive Advantage In Mining Sector: Minister
(MENAFN - IANS) New Delhi, Sep 17 (IANS) Union MoS for Science & Technology and Earth Sciences Dr. Jitendra Singh on Thursday said that India needs to move from a resource advantage to a ...
2026-09-17 06:46:12

ED Raids Multiple States In Ranchi RSS Office Attack Money Laundering Probe
(MENAFN - IANS) Ranchi, Sep 17 (IANS) The Enforcement Directorate (ED) on Thursday carried out raids in several states in connection with its probe into the petrol bomb attack on the Rashtriya ...
2026-09-17 06:46:10

NSE Cannot Trade Its Own Shares On Exchange At Present: SEBI Chief
(MENAFN - IANS) Mumbai, Sep 17 (IANS) Securities and Exchange Board of India (SEBI) Chairman Tuhin Kanta Pandey on Thursday clarified that the regulator has received no formal request for the ...
2026-09-17 06:46:09

Tata Sons Board Approves N Chandrasekaran's 5-Year Reappointment
(MENAFN - AsiaNet News) Tata Sons board approved five-year extension for N Chandrasekaran as the chairman of the Tata Group holding company sources told ANI. The decision was taken at a Tata Sons ...
2026-09-17 06:46:03

NSE Enables India's First Tokenised Corporate Bond Issuances By REC, L&T
(MENAFN - AsiaNet News) First Tokenised Bond Issuances on NSE The National Stock Exchange of India (NSE) has enabled India's first tokenised corporate bond issuances on its Electronic Bidding ...
2026-09-17 06:46:02

Afghan defense minister meets Turkish, Qatari security officials
KABUL, Sept. 17 (Xinhua) -- Afghan Defense Minister Mawlawi Mohammad Yaqoob Mujahid held separate meetings with visiting Director of Trkiye's National Intelligence Organization Ibrahim Kalin and Deputy Secretary of Qatar's National Security Council Hamad bin Khamis Al-Kubaisi, the Ministry of Defense said in statements released on Wednesday evening. During the discussions, the officials focused on advancing rela
2026-09-17 06:45:15

Nomination Committee appointed for AB Electrolux Annual General Meeting 2027
STOCKHOLM , Sept. 17, 2026 /PRNewswire/ -- The members of the Nomination Committee for AB Electrolux Annual General Meeting in 2027 have been appointed. In accordance with decision by the Annual General Meeting, AB Electrolux Nomination Committee shall consist of five members. The Nomination Committee shall include members selected by each of the four largest shareholders in terms of voting rights that wish to participate in the committee, together with the Chair of the Board of AB Electrolux. The members of the Nomination Committee have now been appointed based on the ownership structure as of August 31, 2026. The Nomination Committee consists of: Christian Cederholm, Investor AB, chair Martin Wallin, Lannebo Kapitalförvaltning Alexandra Frenander, Folksam Pia Gisgård, Swedbank Robur Fonder Torbjörn Lööf, Chair of the Board of AB Electrolux. The Nomination Committee will prepare proposals for the Annual General Meeting in 2027 regarding Chairman of the Annual General Meeting, Board members, Chairman of the Board, remuneration for Board members, Auditor, Auditor's fees and, to the extent deemed necessary, proposal regarding amendments of the current instruction for the Nomination Committee. The Annual General Meeting will be held on March 24, 2027, in Stockholm, Sweden. Shareholders who wish to submit proposals to the Nomination Committee should send an email to nominationcommittee@electrolux.com . CONTACT: For further information, please contact Electrolux Press Hotline, +46 8 657 65 07. This information was brought to you by Cision http://news.cision.com https://news.cision.com/electrolux-group/r/nomination-committee-appointed-for-ab-electrolux-annual-general-meeting-2027,c4397096 The following files are available for download: https://mb.cision.com/Main/1853/4397096/4273902.pdf Press release 2026-09-17 Nomination Committee 2027 final
2026-09-17 06:45:00

Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate
HONG KONG , Sept. 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that AK158D1, its investigational next-generation bispecific antibody-drug conjugate (ADC) targeting EGFR and TROP2, has secured Phase I clinical trial clearance from the Center for Drug Evaluation (CDE) under China's National Medical Products Administration (NMPA). The trial will assess the candidate in patients with advanced malignant solid tumors. AK158D1 is Akeso's fourth ADC to enter clinical development and joins the Company's growing clinical-stage ADC portfolio, which includes AK146D1 (TROP2/Nectin-4), AK138D1 (HER3), and AK157D1 (B7-H3). It is also Akeso's second bispecific ADC to reach the clinic, further advancing the Company's global strategy of combining next-generation immuno-oncology (IO2.0) approaches with next-generation ADC platforms (ADC2.0). EGFR (epidermal growth factor receptor) and TROP2 (trophoblast cell surface antigen 2) constitute a highly promising target pair for bispecific ADC therapeutic development, with broad co-expression across a spectrum of solid tumor types. Each target has well-validated anti-tumor mechanisms of action, and their dual targeting holds significant synergistic anti-tumor potential. To date, single-target ADCs directed against either EGFR or TROP2 have been constrained by three key clinical limitations: narrow tumor coverage, off-target toxicity, and multidrug resistance. As a next-generation dual-targeting ADC, AK158D1 integrates the precise tumor recognition enabled by bispecific antibodies, a highly potent cytotoxic payload, and an enhanced safety profile to create a potential breakthrough ADC to address the shortcomings of conventional single-target ADC modalities. Preclinical data for AK158D1 have demonstrated potent anti-tumor activity with a favorable safety profile, supporting its potential as a novel therapeutic option for a wide range of patients, including those who are refractory to, intolerant, or ineligible for existing standard of care regimens. Akeso is advancing its IO2.0 + ADC2.0 strategy, built on proprietary bispecific and multi-specific antibody technology and centered on cornerstone IO2.0 assets including ivonescimab and cadonilimab. Through this approach, the Company is elevating treatment standards for major diseases worldwide and building a broad oncology portfolio to create next-generation standard of care. Leveraging its technological leadership in bispecific and multi-specific antibodies, Akeso is systematically building a comprehensive global IO2.0 + ADC2.0 therapeutic matrix for major diseases worldwide. In the immuno-oncology field, Akeso has two approved bispecific antibodies for cancer treatment. The Company is actively evaluating ivonescimab and cadonilimab in combination with its proprietary next-generation ADC candidates. Increasingly, global partners recognize both ivonescimab and cadonilimab as preferred agents for combination regimens and breakthrough therapy explorations across a wide spectrum of tumor types. In the ADC space, Akeso has built a pipeline of highly differentiated next-generation candidates, including AK146D1, AK138D1, AK157D1 and AK158D1, which are already in clinical development. These agents are designed to address the narrow therapeutic window and safety limitations commonly associated with first-generation ADCs. About AK158D1 AK158D1 is a bispecific ADC developed by Akeso, featuring a humanized antibody that dually targets EGFR and TROP2. Preclinical pharmacodynamic studies have shown strong antigen-binding affinity and robust in vitro and in vivo pharmacological activity. About Akeso Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the Company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multi-specific antibodies and bispecific ADCs. Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval. Akeso is committed to becoming a global leader in biopharmaceuticals through efficient and breakthrough innovation in R&D, developing novel therapies that are first-in-class or best-in-class, and providing better disease solutions for patients around the world. Forward-Looking Statements This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
2026-09-17 06:34:00

GHIT Fund Launches "NTDpedia" to Help Turn Apathy Into Action Against Neglected Tropical Diseases
The interactive educational website makes NTDs understandable to a general audience, the first step toward public support that drives R&D for the 1.5 billion people affected by these diseases TOKYO , Sept. 16, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced the launch of " NTDpedia: Your Guide to Neglected Tropical Diseases ." Designed as an accessible, visually intuitive digital encyclopedia, NTDpedia aims to address a root cause of neglect: Most people have never heard of these diseases. Awareness is the first step; people cannot advocate for, fund, or research a disease they do not know exists. Website URL: https://www.ghitfund.org/ntdpedia/en Overcoming Indifference: Why NTDpedia Matters Today While Sustainable Development Goal 3 (SDG 3) sets a clear mandate to end epidemics of NTDs by 2030 under the banner "Leaving No One Behind," NTDs remain severely underfunded and overlooked. Affected populations are trapped in a vicious cycle: Poverty breeds disease and disease deepens poverty. Lack of clean water and sanitation elevates infection risks, while inadequate healthcare infrastructure leads to severe complications, economic loss, social stigma, and further marginalization. "The greatest barrier to ending NTDs is not just the lack of medical tools but also lack of awareness and societal apathy," said Osamu Kunii, CEO of the GHIT Fund. "NTDpedia was built to transform a distant problem into something people can understand and then care about, which is the first step toward meaningful global action." Key Features of NTDpedia: Connecting Global Challenges to Daily Life Supervised by world-renowned tropical medicine and global health expert Prof. Kenji Hirayama from Nagasaki University, NTDpedia covers the 21 disease groups recognized by the World Health Organization (WHO), including viral, bacterial, parasitic, and fungal infections, as well as snakebite envenoming and noma. To help users intuitively navigate and relate to these complex conditions, the platform introduces two distinct visual discovery frameworks: Four Curated Key Phrases to Personalize the Cause: Climate change: Highlighting diseases that expand into new geographies, including high-income nations, as a warming climate combines with global travel and trade Poor sanitation and poverty: Showing how unsafe water, poor sanitation, and crowded housing keep these diseases circulating and how illness in turn deepens poverty. Children at high risk: Highlighting diseases that fall hardest on children, affecting growth, schooling, and lifelong health. Once common in Japan: Revealing that several of these diseases were once present in Japan and no longer remain in living memory. Categorized Visual Transmission: Diseases are categorized by how they spread and what causes them: parasites, bacteria, viruses, insects, other animals, water/soil, and other routes. Catalyzing R&D and Global Action The GHIT Fund envisions NTDpedia becoming a resource for anyone curious about these diseases, from students and teachers to companies and advocates. Apathy often reflects unfamiliarity rather than indifference. By making these diseases visible and understandable, the GHIT Fund aims to build public support that drives investment in research and development of drugs, vaccines, and diagnostics for NTDs. *Please note that this website was created for general readers who may not have background expertise in the field. Estimates and figures regarding NTDs can differ across various sources; therefore, the content herein has been compiled from multiple references. We kindly ask users to verify the latest data and primary sources prior to referencing this information. The GHIT Fund is a Japan-based international public-private partnership (PPP) fund that was formed between the Government of Japan, multiple pharmaceutical companies, the Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests in and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which afflict the world's vulnerable and underserved populations. In collaboration with global partners, the GHIT Fund mobilizes Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases. https://www.ghitfund.org/ For more information, contact: Katy Lenard at +1-202-494-2584 or klenard@burness.com Eriko Mugitani at +81-36441-2032 or eriko.mugitani@ghitfund.org
2026-09-16 05:00:00

В Сеуле состоялся туркменско-корейский бизнес-форум
В Сеуле состоялся туркменско-корейский бизнес-форум, в котором приняли участие президент Туркменистана Сердар Бердымухамедов, премьер-министр Республики Корея Хан Сон Сук и руководители ведущих компаний двух стран. Участники обсудили практику экономического партнерства и наметили перспективные проекты в высокотехнологичных отраслях, энергетике, инфраструктуре и электроэнергетике. Стороны зафиксировали курс на расширение кооперации по ключевым направлениям. В энергетическом и нефтехимическом секторах акцент сделан на эффективном использовании богатых запасов природного газа для реализации проектов с высокой добавленной стоимостью, включая производство удобрений и газохимию. В сфере водного и лесного хозяйства запланированы работы по модернизации водной инфраструктуры, включая проекты по модернизации Каракум-реки, и внедрению технологий интеллектуального управления ресурсами. Кроме того, партнерство охватывает транспортно-логистический сектор и судостроение — от развития каспийских портов и совместного строительства судов до перехода на экологичный транспорт и умную логистику. Высокотехнологичный сегмент взаимодействия включает производство волоконно-оптических кабелей, стальных труб, техническое обслуживание газовых объектов и реализацию концепции «умных городов». Практическим итогом форума стало подписание 14 меморандумов о взаимопонимании, охватывающих управление водными ресурсами, телекоммуникации, транспорт, энергетическую инфраструктуру, металлургию и академические обмены между университетами двух стран. Правительство Южной Кореи подтвердило готовность оказывать всестороннюю поддержку корейским компаниям для их участия в новых промышленных проектах на территории Туркменистана.
2026-09-16 04:53:06

Korea Town by Boutiqaat Welcomes AXIS-Y, Accelerating the Future of K-Beauty Across the GCC and the Middle East
A strategic partnership strengthening the region's leading destination for Korean beauty ⁠Bringing globally loved Korean skincare closer through a seamless customer experience ⁠A long-term vision to shape the next chapter of K-Beauty in the Middle East HAWALLY, Kuwait , Sept. 16, 2026 /PRNewswire/ -- Korea Town by Boutiqaat proudly announces the official launch of AXIS-Y, one of Korea's most recognized skincare brands, marking another milestone in its mission to bring the latest innovations in Korean beauty closer to customers across the GCC and the Middle East. Renowned for its ingredient-focused philosophy and climate-inspired formulations, AXIS-Y further reinforces Korea Town's position as the region's premier K-beauty destination. AXIS-Y Launch Event at Korea Town Korea Town's expansion strategy continues to gain momentum with nine stores in Kuwait, the recent opening of its flagship in The Avenues, Bahrain, and the upcoming launch of a new store in Qatar. As part of this regional growth, AXIS-Y will be introduced across additional Korea Town locations, ensuring greater accessibility for skincare enthusiasts throughout the Gulf. Looking ahead, Korea Town by Boutiqaat aims to expand its regional presence by the end of 2027 through new store openings, strategic K-beauty partnerships, and stronger offline-to-online customer experiences, building the GCC's most connected and inspiring K-beauty ecosystem. Souha Hasan, General Manager of Korea Town by Boutiqaat, said: "Our partnership with AXIS-Y represents more than a brand launch—it reflects Korea Town's long-term vision of making authentic Korean beauty more accessible across the GCC and the Middle East. As we continue expanding our retail footprint, we remain committed to delivering an integrated omnichannel experience that connects customers with the very best of K-Beauty." The partnership introduces AXIS-Y through a seamless customer journey combining immersive retail experiences, brand activations, and digital accessibility. Customers can discover the brand across Korea Town stores while also shopping the full AXIS-Y range online through Boutiqaat, expanding convenient access across the GCC and the Middle East. Globally recognized for its innovative skincare and hero products such as the Dark Spot Correcting Glow Serum, AXIS-Y delivers targeted solutions for dark spots, uneven skin tone, sensitivity, dehydration, and skin barrier health. Its climate-conscious approach makes the brand highly relevant to today's discerning beauty consumers and a new generation of skincare enthusiasts. Contact: kt.distribution@boutiqaat.com
2026-09-16 04:47:00

Зеленский заявил, что Россия дважды запускала дроны в Молдову, когда там находился его самолет
Президент Украины Владимир Зеленский заявил, что российские дроны дважды за последнее время залетали в воздушное пространство Молдовы, когда там находился его президентский самолет. Об этом он рассказал в интервью CBS News.
2026-09-16 04:39:36

Terminator now: China is exploring humanoid robots for war
At the World Humanoid Robot Games in Beijing, a humanoid robot named Tiangong Ultra ran the 100-meter sprint in a staggering 8.64 seconds, shattering Jamaican sprinter Usain Bolt’s legendary human world record of 9.58 seconds. The internet laughed at the robots’ awkward, lurching finishes and spectacular falls – but the laughter masked a chilling reality. [...] The post Terminator now: China is exploring humanoid robots for war appeared first on Asia Times .
2026-09-16 04:33:07

TAT spotlights Bangkok Art Biennale 2026 as a contemporary citywide art experience
Angels & Mara transforms temples, museums, landmarks and public spaces into an art route for culture-led travel BANGKOK , Sept. 16, 2026 /PRNewswire/ -- The Tourism Authority of Thailand (TAT) is highlighting Bangkok Art Biennale 2026 (BAB 2026) as a citywide contemporary art experience that will strengthen Bangkok's position as a global art destination. Scheduled from 29 October 2026 to 28 February 2027 under an Angels & Mara theme, the fifth edition brings Thai and international artists into dialogue with the capital's heritage, spirituality, urban life and creative future. Angels & Mara will shape Bangkok Art Biennale 2026 as an accessible art route across the Thai capital, inviting visitors to encounter Bangkok through contemporary art, heritage settings, creative districts and everyday urban life from 29 October 2026 to 28 February 2027. TAT Governor Ms. Thapanee Kiatphaibool said, "Bangkok Art Biennale 2026 reflects TAT's direction to position Thailand as a high-value and meaningful destination, where culture, creativity and contemporary identity create deeper reasons to travel. By turning Bangkok into a citywide platform for artistic discovery, Angels & Mara strengthens the Thai capital's global visibility, supports the Festival Economy, and connects visitors with experiences that bring together heritage, imagination and the creative energy of Amazing Thailand." Angels & Mara shapes the citywide platform that explores the tension between guardians of light and forces of temptation. Drawing on religious, cultural and philosophical traditions, BAB 2026 examines the dualities that define modern life, from hope and despair to spirituality and materialism, memory and forgetting, desire and restraint. Set in Bangkok, whose Thai name, Krung Thep , means City of Angels, the theme gives visitors a deeper look into the capital, while offering artists a powerful framework to reflect on the uncertainty, conflict and transformation of modern life. The programme features a growing roster of artists and collectives from Thailand and around the world, working across painting, sculpture, photography, performance art, film and multimedia. The line-up reinforces BAB 2026 as an international platform for artistic dialogue, stimulating conversation across cultures, generations and disciplines. BAB 2026 will unfold across temples, museums, cultural institutions, educational spaces and major public venues. Locations include Wat Arun (Temple of Dawn), Wat Pho (Temple of the Reclining Buddha), Wat Prayoon (Temple of the Iron Fences), Museum Siam, Bangkok Art and Culture Centre, One Bangkok, centralwOrld, Siam Paragon, the National Museum Bangkok and the Art Centre, Silpakorn University. Together, these venues connect Bangkok's historic quarters, riverfront communities, civic landmarks and emerging areas, offering visitors a new art route to explore the capital. Against this urban backdrop, TAT will connect BAB 2026 with Thailand's wider tourism appeal, encouraging visitors to experience Bangkok through contemporary art, heritage sites, creative districts and everyday city life. This approach supports culture-led travel and reinforces the capital as a place where heritage, creativity and contemporary urban culture converge. The festival is a collaboration of Thailand's cultural, tourism, government and private-sector partners, with Thai Beverage Public Company Limited as a major supporter since 2018. This shared commitment reinforces Bangkok's appeal as a regional centre for contemporary art and extends the value of art into tourism, education, public engagement and the wider economy. Founded in 2017 and first staged in 2018, Bangkok Art Biennale was created to transform Bangkok into one of Southeast Asia's leading modern art destinations. Previous editions have attracted more than 3.5 million visitors and presented works by over 300 artists from Asia, Europe, the Americas, Oceania and Africa. Meanwhile, the pandemic-era BAB Virtual Venue reached over 2.3 million online viewers worldwide. More information, including the latest participating artists, artworks, venues and public programmes, is available through official Bangkok Art Biennale channels. Website: www.tatnews.org
2026-09-16 04:30:00

Президент Туркменистана встретился со спикером Национальной ассамблеи Республики Корея
В рамках программы государственного визита в Республику Корея президент Туркменистана Сердар Бердымухамедов провел встречу со спикером Национальной ассамблеи Кореи Чо Чжон Сиком. Переговоры были посвящены приоритетам двустороннего взаимодействия и углублению межпарламентского диалога. В ходе переговоров было подчеркнуто, что законодательный орган Кореи готов содействовать практическому сближению технологических возможностей Сеула и богатого ресурсного потенциала Туркменистана для достижения ощутимых экономических результатов. На встрече также отмечалась положительная динамика в культурно-гуманитарных связях и сфере академического обмена. Этому способствовали запуск прямого авиасообщения между Ашхабадом и Сеулом, а также растущий интерес к корейской культуре и языку в регионе. Президент Сердар Бердымухамедов заявил, что Ашхабад придает особое значение всестороннему развитию отношений с Южной Кореей. Глава государства выделил институциональную роль парламентов двух стран в укреплении взаимного доверия и поддержал намерение расширять контакты по линии законодательных органов.
2026-09-16 04:19:12

Plain speak on AI controls: What, exactly, would we have to stop?
In one of our more important write-ups early this year, we discussed how AI is going to be our economics and AI is going to be our politics for years and decades ahead. The debate over controlling it is making that plain. We normally prefer to reach our conclusion with the reader. With so much being written, [...] The post Plain speak on AI controls: What, exactly, would we have to stop? appeared first on Asia Times .
2026-09-16 04:16:59

Министр Юстиции Монголии освобожден от занимаемой должности
Как сообщает Zogii.mn, Премьер-министр Монголии Учрал Ням-Осор принял решение освободить от занимаемой должности Амарсайхана Сайнбуяна министра юстиции и внутренних дел страны. По мнению главы кабинета министров, ситуация, возникшая в сфере юстиции и внутренних дел, достигла критической отметки, создавая угрозу нормальной деятельности ведомства, ответственного за обеспечение внутренней безопасности, и подрывая доверие граждан.
2026-09-16 04:15:26

Президент Сердар Бердымухамедов находится с государственным визитом в Республике Корея
В Сеуле состоялись переговоры на высшем уровне между президентом Туркменистана Сердаром Бердымухамедовым, находящимся с государственным визитом в Республике Корея, и президентом Республики Корея Ли Чжэ Мёном. По итогам встречи в присутствии глав государств был подписан пакет двусторонних документов, призванных вывести партнерство Ашхабада и Сеула на новый уровень. Повестка переговоров охватила широкий спектр направлений практического взаимодействия. Главы государств рассмотрели возможности расширения участия корейских компаний в реализации крупномасштабных проектов по строительству промышленных предприятий, объектов химической отрасли, а также модернизации железнодорожной сети Туркменистана. Особое внимание стороны уделили промышленной кооперации. Руководители двух государств высоко оценили взаимовыгодную модель сотрудничества в судостроительной отрасли, предполагающую совместное строительство судов на территории Туркменистана силами корейских и туркменских специалистов. Кроме того, партнерство затронет сферы строительства новых городов, внедрение искусственного интеллекта, а также совместное решение экологических задач. Фундаментом для реализации намеченных планов стал подписанный пакет документов, включающий Соглашение о защите инвестиций, Соглашение о взаимной помощи в таможенных делах и Меморандум о сотрудничестве в области интеллектуальной собственности. Также были заключены соглашения в сферах химической промышленности, машиностроения, правового взаимодействия, охраны окружающей среды и молодежных обменов.
2026-09-16 04:03:20